和黄医药宣布“索乐匹尼布”3期研究获阳性顶线结果

药渡
Jan 09

1月7日,和黄医药宣布,新型脾酪氨酸激酶(Syk)抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血成人患者的ESLIM-02研究的3期注册阶段已达到第5至24周治疗期间持久血红蛋白(Hb)应答这一主要终点。自身免疫性溶血性贫血(AIHA)是一种自身免疫性疾病,是由于产生抗自身红细胞的抗体,而导致红细胞的破坏所造成的疾病。患者常出现疲劳等症状,影响生活质量。若病情未得到有效控制,在严重个案中甚至...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10